Biotech IPO: Stemline Therapeutics, an emerging biotech company, successfully completed its biotech IPO yesterday with shares rising 18% on opening.
Stemline increased the number of shares in the initial public offering, or IPO, by about one million, bringing the offering's value to $33 million, or $6 million more than the top estimate previously outlined in documents filed with the Securities and Exchange Commission.
Stemline Therapeutics, an emerging biotech company, is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase 1/2 studies of advanced cancer patients.
View: Financing Scorecard - the top deals by value
Signup: Current Partnering Dealmakers News - weekly email newsletter reviewing the previous weeks deal trends
Signup: Current Agreements Deals Review - monthly review of previous months deals, M&A and financings
Subscribe: Current Agreements - life science licensing, partnering, deals, M&A and financings database